No Shortage of Hopefuls in the Multibillion-Dollar Blood Thinner Business
Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
plavix
AstraZeneca’s Heart Drug Beats Plavix in Phase III Study
Blood-thinning drug Plavix racks up over $8 billion in annual sales, but the blockbuster medication may have some new competition.